先聲藥業(02096.HK)治療晚期腫瘤抑制劑臨床試驗獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)治療晚期腫瘤抑制劑臨床試驗獲批

阿思達克 03-23 02:31

先聲藥業(02096.HK)公布，集團自主研發的抗腫瘤口服蛋白精氨酸甲基轉移(酉每)5(PRMT5)抑制劑SIM0272已獲國家藥品監督管理局簽發的藥物臨床試驗批准通知書，擬用於開展治療晚期惡性腫瘤的臨床試驗。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)治療晚期腫瘤抑制劑臨床試驗獲批

Services

About Us

Agreement Statement